What is HC Wainwright's Estimate for ENTA FY2025 Earnings?

Key Points

• HC Wainwright raised its FY2025 earnings per share estimate for Enanta Pharmaceuticals from ($4.69) to ($4.16), maintaining a "Buy" rating and a price target of $20.00.
• The biotechnology company reported a quarterly earnings beat with ($0.85) earnings per share, outperforming the consensus estimate of ($1.25), alongside a revenue of $18.31 million.
• Various institutional investors have increased their stakes in Enanta Pharmaceuticals, with hedge funds now owning 94.99% of the company's stock.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities research analysts at HC Wainwright raised their FY2025 earnings per share estimates for Enanta Pharmaceuticals in a report released on Tuesday, August 12th. HC Wainwright analyst B. Folkes now anticipates that the biotechnology company will earn ($4.16) per share for the year, up from their prior estimate of ($4.69). HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals' Q4 2025 earnings at ($1.19) EPS, FY2026 earnings at ($3.52) EPS, FY2027 earnings at ($3.27) EPS, FY2028 earnings at ($2.12) EPS and FY2029 earnings at ($2.11) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.25) by $0.40. The firm had revenue of $18.31 million during the quarter, compared to analysts' expectations of $16.21 million. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.

Several other equities research analysts have also recently weighed in on the company. Wall Street Zen raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, June 22nd. JMP Securities increased their price objective on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 12th.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA traded up $0.26 during mid-day trading on Thursday, hitting $8.00. The company's stock had a trading volume of 133,410 shares, compared to its average volume of 176,188. Enanta Pharmaceuticals has a one year low of $4.09 and a one year high of $13.43. The firm has a market capitalization of $171.04 million, a PE ratio of -1.85 and a beta of 0.88. The stock's 50-day moving average is $7.40 and its two-hundred day moving average is $6.50.

Institutional Trading of Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sio Capital Management LLC boosted its holdings in Enanta Pharmaceuticals by 1.0% in the second quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company's stock valued at $1,352,000 after acquiring an additional 1,770 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock worth $41,000 after buying an additional 2,274 shares during the last quarter. Invesco Ltd. boosted its holdings in Enanta Pharmaceuticals by 4.3% during the second quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company's stock worth $475,000 after buying an additional 2,607 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Enanta Pharmaceuticals by 8.2% during the 1st quarter. American Century Companies Inc. now owns 40,004 shares of the biotechnology company's stock valued at $221,000 after purchasing an additional 3,042 shares in the last quarter. Finally, CWM LLC lifted its holdings in shares of Enanta Pharmaceuticals by 22.1% during the 2nd quarter. CWM LLC now owns 21,464 shares of the biotechnology company's stock valued at $162,000 after purchasing an additional 3,879 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.